HomeCompareNXCLF vs JNJ

NXCLF vs JNJ: Dividend Comparison 2026

NXCLF yields 1.97% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.3K in total portfolio value· pulled ahead in Year 5
10 years
NXCLF
NXCLF
● Live price
1.97%
Share price
$1.52
Annual div
$0.03
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$0.20
Full NXCLF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NXCLF vs JNJ

📍 JNJ pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNXCLFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NXCLF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NXCLF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NXCLF
Annual income on $10K today (after 15% tax)
$167.76/yr
After 10yr DRIP, annual income (after tax)
$0.17/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NXCLF + JNJ for your $10,000?

NXCLF: 50%JNJ: 50%
100% JNJ50/50100% NXCLF
Portfolio after 10yr
$25.1K
Annual income
$2,344.80/yr
Blended yield
9.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NXCLF
No analyst data
Altman Z
-83.1
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NXCLF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNXCLFJNJ
Forward yield1.97%2.13%
Annual dividend / share$0.03$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$20.0K$30.3K
Annual income after 10y$0.20$4,689.40
Total dividends collected$198.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NXCLF vs JNJ ($10,000, DRIP)

YearNXCLF PortfolioNXCLF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,799$98.68$10,592$272.30+$207.00NXCLF
2$11,604$49.80$11,289$357.73+$315.00NXCLF
3$12,442$25.01$12,123$472.89+$319.00NXCLF
4$13,325$12.53$13,141$629.86+$184.00NXCLF
5← crossover$14,264$6.27$14,408$846.81$144.00JNJ
6$15,266$3.14$16,021$1,151.60$755.00JNJ
7$16,336$1.57$18,122$1,588.22$1.8KJNJ
8$17,480$0.78$20,930$2,228.20$3.5KJNJ
9$18,704$0.39$24,792$3,191.91$6.1KJNJ
10$20,014$0.20$30,274$4,689.40$10.3KJNJ

NXCLF vs JNJ: Complete Analysis 2026

NXCLFStock

LIFULL Co., Ltd. provides real estate information services in Japan. It offers LIFULL HOME'S, a site of real estate and housing information; LIFULL Revitalize Rural Japan that suggest new lifestyles to people in Japan based on refurbishment of abandoned houses; LIFULL Move that provides reviews and rankings of the moving companies; LIFULL Nursing Care, a special care facility searching web service; LIFULL Life Plan that provide the opportunity for updating life plan; LIFULL FLOWER, an online flower gift shop; and LIFULL Investment, a money funding website. The company also provides LIFULL FaM that enables working mothers balance childcare with work while pursuing a career; LIFULL rental spaces, a site for rental spaces and meeting rooms, event venues, and other rental facilities; LIFULL Storage, a storage space searching web service; LIFULL HUB, a shared office; LIFULL Fab to expand possibilities of design and craftsmanship; LIFULL Table, a mixed-style deli restaurant; and LIFULL Marketing Partners that offers full Web assistance for real estate related companies. In addition, it offers LivingAnywhere Commons, a community to live; instant house products; LIFULL Real Estate Crowdsourcing, an online advertising platform for property crowd funding projects; Trovit, an aggregation website; and Mitula, a site that provides information in real estate and housing, used cars, recruitment, and fashion. The company was formerly known as NEXT Co., Ltd. and changed its name to LIFULL Co., Ltd.in April 2017. LIFULL Co., Ltd. was founded in 1997 and is headquartered in Tokyo, Japan.

Full NXCLF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NXCLF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NXCLF vs SCHDNXCLF vs JEPINXCLF vs ONXCLF vs KONXCLF vs MAINNXCLF vs ABBVNXCLF vs MRKNXCLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.